Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Sunshine Biopharma (SBFM) over the last 10 years, with Q3 2025 value amounting to $8040.0.

  • Sunshine Biopharma's Capital Expenditures fell 9844.49% to $8040.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $278130.0, marking a year-over-year decrease of 7627.06%. This contributed to the annual value of $1.7 million for FY2024, which is 191463.2% up from last year.
  • Per Sunshine Biopharma's latest filing, its Capital Expenditures stood at $8040.0 for Q3 2025, which was down 9844.49% from $160000.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Capital Expenditures registered a high of $974513.0 during Q2 2024, and its lowest value of -$382363.0 during Q4 2023.
  • For the 4-year period, Sunshine Biopharma's Capital Expenditures averaged around $165383.8, with its median value being $82768.5 (2024).
  • In the last 5 years, Sunshine Biopharma's Capital Expenditures tumbled by 29711.26% in 2023 and then soared by 526646.25% in 2024.
  • Quarter analysis of 4 years shows Sunshine Biopharma's Capital Expenditures stood at $193982.0 in 2022, then tumbled by 297.11% to -$382363.0 in 2023, then soared by 126.83% to $102600.0 in 2024, then plummeted by 92.16% to $8040.0 in 2025.
  • Its Capital Expenditures stands at $8040.0 for Q3 2025, versus $160000.0 for Q2 2025 and $7490.0 for Q1 2025.